Artificial nucleic acid molecule comprising novel synthetic 5'UTR and uses thereof

WO2026038592A1PCT designated stage Publication Date: 2026-02-19CDMOGEN CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2024/012135
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Filing Date
2024-08-14
Publication Date
2026-02-19

AI Technical Summary

Technical Problem

mRNA vaccines face challenges due to lower structural stability compared to DNA, limiting their industrial application and requiring large quantities of plasmid vectors for production, which are scarce.

Method used

Development of a novel synthetic 5'UTR and an artificial nucleic acid molecule, integrated into a vector, to enhance mRNA stability and efficiency, allowing for high protein expression even with small doses.

Benefits of technology

The novel 5'UTR significantly increases mRNA expression, enabling efficient production of vaccines with reduced vector requirements.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2024012135_19022026_PF_FP_ABST
    Figure KR2024012135_19022026_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a novel synthetic 5' UTR, an artificial nucleic acid molecule comprising the 5' UTR, a vector comprising the artificial nucleic acid molecule, and a vaccine composition comprising same. The plasmid vector comprising the novel synthetic 5' UTR significantly increases mRNA expression, and thus can be advantageously used in the production of various drugs such as vaccines.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • 3-hydroxypropionic acid-producing recombinant microorganism and method of producing 3-hydroxypropionic acid using the same

    KR101760340B1

  • 5'-UTR for improving conversion of glucose to glycerol and uses thereof

    KR102659292B1

  • Artificial nucleic acid molecules comprising a 5′TOP UTR

    US10080809B2

  • Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression

    WO2009042971A2

  • Artificial nucleic acid molecules

    WO2016107877A1